The global Pet Pharmaceuticals market was valued at 145.06 Million USD in 2021 and will grow with a CAGR of 7% from 2021 to 2027, based on Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Pet pharmaceutical refers specifically to medicines given to pets.In terms of the purpose of use, pet drugs are mainly used by dogs and cats. Through drug prevention and treatment of pet diseases, the cure rate of pet diseases can be improved, the physical and mental health of pets can be guaranteed, and the quality of life of pets can be improved. In terms of clinical significance, the application of pet drugs can provide clinical data for the research and development of new pet drugs, and promote the replacement and upgrading of new pet drugs. North America is the largest production and consumption region market with about 49% revenue market share in 2019. The key players are Zoetis, Boehringer Ingelheim, Merck, Elanco, Virbac, Dechra Veterinary Products, Ceva, Vetoquinol, Ouro Fino Saude, Norbrook, Jindun, Chopperlvya Animal Health, CAHIC etc. Zoetis is leader company with about 36% revenue market share in 2019.
By Market Verdors:
Key Indicators Analysed
Key Reasons to Purchase